KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Other Accumulated Expenses (2018 - 2026)

Bristol Myers Squibb has reported Other Accumulated Expenses over the past 16 years, most recently at $12.6 billion for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 23.6% to $12.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.6 billion through Mar 2026, down 23.6% year-over-year, with the annual reading at $17.6 billion for FY2025, 3.01% down from the prior year.
  • Other Accumulated Expenses was $12.6 billion for Q1 2026 at Bristol Myers Squibb, down from $17.6 billion in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $19.3 billion in Q3 2025 and troughed at $12.4 billion in Q1 2022.
  • The 5-year median for Other Accumulated Expenses is $15.9 billion (2023), against an average of $15.5 billion.
  • Year-over-year, Other Accumulated Expenses grew 22.48% in 2024 and then decreased 23.6% in 2026.
  • A 5-year view of Other Accumulated Expenses shows it stood at $14.6 billion in 2022, then grew by 8.9% to $15.9 billion in 2023, then rose by 14.11% to $18.1 billion in 2024, then fell by 3.01% to $17.6 billion in 2025, then dropped by 28.24% to $12.6 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Other Accumulated Expenses are $12.6 billion (Q1 2026), $17.6 billion (Q4 2025), and $19.3 billion (Q3 2025).